Platelet-directed therapies and coronary artery bypass grafting

Area of Science:

• Cardiology
• Cardiovascular Surgery
• Pharmacology

Background:

• Coronary artery bypass grafting (CABG) reduces cardiovascular morbidity and mortality in high-risk patients.
• Hemorrhagic complications remain a significant concern following CABG, impacting patient outcomes and healthcare costs.
• Platelet-directed therapies, while reducing ischemic events, concurrently elevate bleeding risks.

Purpose of the Study:

• To evaluate the balance between ischemic benefits and bleeding risks associated with antiplatelet agents in patients undergoing CABG.
• To assess the specific risks of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel or prasugrel in the perioperative CABG setting.
• To explore the potential of reversible P2Y12 receptor antagonists to mitigate bleeding complications.

Main Methods:

• Review of existing literature on antiplatelet therapy and CABG outcomes.
• Analysis of the risks and benefits of aspirin monotherapy versus dual antiplatelet therapy (DAPT).
• Discussion of the implications of perioperative antiplatelet agent management on patient safety and outcomes.

Main Results:

• Preoperative low-dose aspirin is likely to provide benefits that outweigh its bleeding risk.
• Dual antiplatelet therapy (aspirin plus clopidogrel or prasugrel) is linked to a significant increase in bleeding and its complications.
• The efficacy and safety of reversible P2Y12 inhibitors in reducing bleeding risk require further investigation.

Conclusions:

• Careful consideration of antiplatelet therapy is crucial in CABG patients to optimize outcomes.
• Physicians must weigh the potential for increased bleeding against the benefits of antiplatelet agents.
• Large prospective studies are necessary to clarify the role of newer antiplatelet agents in the context of CABG.